

# INFECTIOUS DISEASES IV PANEL

---

## Series Editors:

### John E. Murphy, Pharm.D., FCCP, FASHP

*Professor of Pharmacy Practice and Science  
Associate Dean  
University of Arizona College of Pharmacy  
Tucson, Arizona*

### Mary Wun-Len Lee, Pharm.D., FCCP, BCPS

*Vice President and Chief Academic Officer  
Pharmacy and Optometry Education  
Professor of Pharmacy Practice  
Midwestern University  
Chicago College of Pharmacy  
Downers Grove, Illinois*

## Faculty Panel Chair:

### Kathryn R. Matthias, Pharm.D., BCPS (AQ-ID)

*Assistant Professor  
Department of Pharmacy Practice & Science  
University of Arizona  
Tucson, Arizona*

## LUNG ABSCESSSES

### Authors

#### Elias B. Chahine, Pharm.D., FCCP, BCPS-AQ ID

*Associate Professor of Pharmacy Practice  
Department of Pharmacy Practice  
Palm Beach Atlantic University  
Lloyd L. Gregory School of Pharmacy  
West Palm Beach, Florida  
Clinical Pharmacy Specialist  
Department of Pharmacy Services  
Wellington Regional Medical Center  
Wellington, Florida*

#### Lamis R. Karaoui, Pharm.D., BCPS

*Clinical Associate Professor  
Director of Experiential Education  
Department of Pharmacy Practice  
Lebanese American University, School of Pharmacy  
Byblos, Lebanon*

### Reviewers

#### P. Brandon Bookstaver, Pharm.D., FCCP, FIDSA, BCPS, AAHIVP

*Associate Professor  
Vice Chair  
South Carolina College of Pharmacy  
University of South Carolina  
Columbia, South Carolina*

#### Joseph E. Blais, BSPHarm, BCPS

*Research Assistant, Honorary Tutor  
Department of Pharmacology and Pharmacy  
The University of Hong Kong  
Hong Kong*

#### Lan N. Bui, Pharm.D., BCPS

*Clinical Pharmacy Fellow in Outcomes Research  
Pharmacy Department  
Houston Methodist Hospital  
Houston, Texas*

#### Tristan Lindfelt, Pharm.D., BCPS, BCACP, BCOP

*Drug Interactions Editor  
Epocrates  
Athenahealth  
San Francisco Bay Area, California  
Associate Professor  
Clinical Sciences Department  
Touro University California College of Pharmacy  
Vallejo, California*

## C. DIFFICILE INFECTION

### Author

#### Donna Lisi, Pharm.D., BCPS, BCPP, BCGP

*Adjunct Faculty  
Union County College  
Allied Health  
Plainfield, New Jersey*

### Reviewers

#### David E. Nix, Pharm.D., FCCP, BCPS-AQ ID

*Professor  
University of Arizona  
Tucson, Arizona*

#### Janice S. Kerr, Pharm.D., BCPS, BCACP

*Clinical Pharmacist (Abdominal Transplant)  
Pharmacist Specialist  
UC San Diego Health  
La Jolla, California*

#### Christina J. Dewar, Pharm.D., BCPS

*Pharmacy Residency Program Director  
Pharmacy Department  
Aultman Hospital  
Canton, Ohio*

#### Cody Null, Pharm.D., BCPS, BCCCP

*Emergency Medicine Pharmacist  
Pharmacy Department  
Baptist Health Medical Center  
Little Rock, Arkansas*

**Ted Hancock, Pharm.D., FASCP, BCGP, BCACP, CTTS, CPP**

*Assistant Professor*

Department of Pharmacy Practice

Campbell University College of

Pharmacy and Health Sciences

Buies Creek, North Carolina

**Ralph H. Raasch, Pharm.D., FCCP, BCPS**

*Associate Professor of Pharmacy (retired)*

Division of Practice Advancement and Clinical Education

Eshelman School of Pharmacy

The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Infectious Diseases IV chapters:

**Anne L. Hume, Pharm.D., FCCP, BCPS**

*Professor of Pharmacy*

Department of Pharmacy Practice

University of Rhode Island

Kingston, Rhode Island

*Adjunct Professor of Family Medicine*

Alpert School of Medicine at Brown University

Providence, Rhode Island

## DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** P. Brandon Bookstaver (Rockpointe, Inc., FreeCe.com); Elias B. Chahine (Allergan plc); Paulina Deming (Gilead); Geneen M. Gibson (American Society of Health-System Pharmacists, State of Georgia Department of Public Health, Georgia Society of Health-System Pharmacists, ACCP Infectious Diseases PRN); Hanna Phan (Vertex Pharmaceuticals Inc.); Melissa Ruble (Florida Pharmacy Association)

**Stock Ownership:** Scot Walker (Apple, Merck, Pfizer)

### **Royalties:**

**Grants:** Lan N. Bui (Texas Southern University and Houston Methodist Research Institute); Wasim S. El Nekidy (The Kidney Foundation of Canada); Nicholas Lehman (Pfizer, Inc.); David E. Nix (NIH/NIAID Valley Fever Center); Sarah Petite (American Society of Health-System Pharmacists); Hanna Phan (Cystic Fibrosis Foundation, Success with Treatment Research Consortium, National Heart, Lung, and Blood Institute); Melissa Ruble (University of South Florida College of Pharmacy); Kayla R. Stover (Astellas Pharma U.S. Inc.)

**Honoraria:** Elias B. Chahine (Merck & Co, Inc.)

**Other:** Mary L. Foss (Employment Pfizer [spouse or significant other])

**Nothing to disclose:** Joseph E. Blais; John Boreyko; Andrew P. Clark; Philip Chung; Christina J. Dewar; Gabriella A. Douglass; Rasha Abd Elsalam Elshenawy, Sr.; Miki A. Goldwire; Ted Hancock; Susan M. Holden; Vanthida Huang; Lulu Jin; Lamis R. Karaoui; Michael B. Kays; Janice S. Kerr; Roger D. Lander; Jennifer Le; Helen S. Lee; Tristan Lindfelt; Donna Lisi; Michelle T. Martin; Cody Null; LaDonna M. Oelschlaeger; Sumanta B. Paul; Polina Plotkin; Kellie S. Rose; Sean D. Stewart; Sylvia S. Stoffella; Meghan K. Sullivan; Evan Williams

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. For more information about the BPS recertification process, [click here](#).

Questions regarding BPS specialty recertification should be directed to:

### [Board of Pharmacy Specialties](#)

2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591